1.80
0.02 (1.12%)
| Previous Close | 1.78 |
| Open | 1.81 |
| Volume | 790,879 |
| Avg. Volume (3M) | 1,464,482 |
| Market Cap | 152,989,744 |
| Price / Sales | 77.32 |
| Price / Book | 4.96 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -0.770 |
| Total Debt/Equity (MRQ) | 416.80% |
| Current Ratio (MRQ) | 4.66 |
| Operating Cash Flow (TTM) | -33.87 M |
| Levered Free Cash Flow (TTM) | -19.45 M |
| Return on Assets (TTM) | -41.29% |
| Return on Equity (TTM) | -307.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Milestone Pharmaceuticals Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.71% |
| % Held by Institutions | 22.25% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Propel Bio Management, Llc | 30 Jun 2025 | 1,791,557 |
| Alta Fundamental Advisers Llc | 30 Jun 2025 | 1,398,977 |
| Bml Capital Management, Llc | 30 Jun 2025 | 1,136,091 |
| Simplify Asset Management Inc. | 30 Jun 2025 | 990,000 |
| Lion Point Capital, Lp | 30 Jun 2025 | 548,806 |
| Boxer Capital, Llc | 30 Sep 2024 | 309,007 |
| Valeo Financial Advisors, Llc | 30 Jun 2025 | 130,699 |
| Cascades Capital Asset Management, Llc | 30 Jun 2025 | 67,135 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Aug 2025 | Announcement | Milestone® Pharmaceuticals to Present at Upcoming Conferences |
| 12 Aug 2025 | Announcement | Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update |
| 11 Jul 2025 | Announcement | Milestone Pharmaceuticals Announces Proposed Public Offering |
| 11 Jul 2025 | Announcement | Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray |
| 11 Jul 2025 | Announcement | Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants |
| 16 Jun 2025 | Announcement | Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |